Nxera Pharma Triumphs at Citeline Japan Awards
Tokyo, Japan and Cambridge, UK – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; JPX: 4565) proudly announces its recognition as Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards. This esteemed event, held in Tokyo, highlighted the company’s significant achievements in the biotech industry.
Significance of the Citeline Japan Awards
The Citeline Japan Awards, a prestigious initiative akin to the global Scrip Awards, celebrate remarkable advancements within Japan's pharmaceutical and biotechnology sectors. For over 20 years, these awards have acknowledged the integral contributions of Japanese companies in the global healthcare market. A panel of experts from various fields evaluates the nominees, ensuring only the best are honored.
Achievements Leading to Recognition
Nxera Pharma's impressive award for Biotech Company of the Year reflects its stellar performance during the evaluation period. The milestone event was the acquisition of Idorsia's pharmaceutical operations in Japan and South Korea, completed in mid-2023. This strategic move significantly expanded Nxera's capabilities and product offerings, effectively doubling its operational footprint in the region.
By integrating a seasoned clinical and commercial development team along with accessing nearly launched products and potential Phase 3 assets, Nxera established a robust foundation for future growth. This transformation not only boosted the company’s portfolio but also necessitated a rebranding from Sosei-Heptares to Nxera Pharma earlier this year.
Strategic Partnerships and Financial Growth
During this period, Nxera's proactive approach in securing financing culminated in winning the Financing Deal of the Year award. In late 2023, the Company successfully raised approximately JPY8 billion (around USD54 million) through investments linked to the newly formed OPF1 fund, which is driven by Japan's government-backed initiatives to foster innovative businesses.
Future Aspirations of Nxera Pharma
At the heart of Nxera Pharma’s strategy is a commitment to developing innovative medicines that address unmet medical needs. The company has established a promising partnership with Boehringer Ingelheim to develop its GPR52 agonists for schizophrenia treatment. This deal, potentially valued up to EUR 670 million, alongside royalties, underscores Nxera’s focus on collaboration to enhance its pipeline.
The Nxera Pharma Team's Dedication
Chris Cargill, the President and CEO of Nxera Pharma, expressed immense pride in the team’s dedication, stating that these awards reflect the hard work put forth by their global team. The recognition is not just an accolade but a motivation to push forward in delivering transformative medicines to patients in Japan and beyond.
About Nxera Pharma
Nxera Pharma, formerly known as Sosei Heptares, is a biopharmaceutical company driven by innovative technology. With a focus on developing specialty medicines, Nxera is committed to enhancing patients’ lives globally. Currently, the company manages an expansive pipeline of over 30 active programs in various therapeutic areas, including neurology, immunology, and rare diseases.
Employing over 350 individuals across multiple global locations, including key cities in Japan, the UK, Switzerland, and South Korea, Nxera is dedicated to addressing crucial unmet medical needs while leveraging its GPCR-targeted drug discovery platform, NxWave™, for sustainable development of leading candidates.
Frequently Asked Questions
What awards did Nxera Pharma win?
Nxera Pharma won the Biotech Company of the Year and Financing Deal of the Year awards at the Citeline Japan Awards.
When was Nxera Pharma founded?
Nxera Pharma was formerly known as Sosei Heptares and rebranded earlier this year.
What strategic acquisition did Nxera Pharma make?
The company acquired the pharmaceutical operations of Idorsia in Japan and South Korea in mid-2023, doubling its operational capacity.
What is the future focus of Nxera Pharma?
Nxera aims to develop innovative medicines to meet unmet medical needs and has partnered with Boehringer Ingelheim for schizophrenia treatments.
How many programs does Nxera Pharma have in its pipeline?
Nxera is currently advancing over 30 active programs across various therapeutic areas.
